These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

140 related articles for article (PubMed ID: 17404515)

  • 1. The immunogenicity and reactogenicity of a new DTPw-HBV vaccine as a primary and booster vaccination course in healthy infants.
    Prymula R; David MP; Lefevre I; Kohl I; Stefkovicová M
    Hum Vaccin; 2007; 3(4):121-6. PubMed ID: 17404515
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Immunogenicity, reactogenicity and safety of three-dose primary and booster vaccination with combined diphtheria-tetanus-whole-cell pertussis-hepatitis B-reduced antigen content Haemophilus influenzae type b vaccine in Filipino children.
    Gatchalian SR; Ramakrishnan G; Bock HL; Lefevre I; Jacquet JM
    Hum Vaccin; 2010 Aug; 6(8):664-72. PubMed ID: 20657177
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A new DTPw-HBV/Hib vaccine is immunogenic and safe when administered according to the EPI (Expanded Programme for Immunization) schedule and following hepatitis B vaccination at birth.
    Gatchalian S; Reyes M; Bernal N; Lefevre I; David MP; Han HH; Bock HL; Wolter J; Schuerman L
    Hum Vaccin; 2005; 1(5):198-203. PubMed ID: 17012860
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Primary and booster vaccination in Latin American children with a DTPw-HBV/Hib combination: a randomized controlled trial.
    Espinoza F; Tregnaghi M; Gentile A; Abarca K; Casellas J; Collard A; Lefevre I; Jacquet JM
    BMC Infect Dis; 2010 Oct; 10():297. PubMed ID: 20950456
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A new DTPw-HBV/Hib vaccine: immune memory after primary vaccination and booster dosing in the second year of life.
    Gatchalian S; Reyes M; Bermal N; Chandrasekaran V; Han HH; Bock HL; Lefevre I
    Hum Vaccin; 2008; 4(1):60-6. PubMed ID: 18376148
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Immunogenicity and reactogenicity of combined versus separately administered DTPw-HBV and Hib vaccines given to healthy infants at 2, 4 and 6 months of age, with a booster at 18 months.
    Riedemann S; Reinhardt G; Jara J; Rios R; Wenzel MS; Willems P; Bock HL
    Int J Infect Dis; 2002 Sep; 6(3):215-22. PubMed ID: 12718838
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Immunogenicity and safety of primary and booster vaccination with 2 investigational formulations of diphtheria, tetanus and Haemophilus influenzae type b antigens in a hexavalent DTPa-HBV-IPV/Hib combination vaccine in comparison with the licensed Infanrix hexa.
    Vesikari T; Rivera L; Korhonen T; Ahonen A; Cheuvart B; Hezareh M; Janssens W; Mesaros N
    Hum Vaccin Immunother; 2017 Jul; 13(7):1505-1515. PubMed ID: 28340322
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A new DTPw-HB/Hib combination vaccine for primary and booster vaccination of infants in Latin America.
    Tregnaghi M; López P; Rocha C; Rivera L; David MP; Rüttimann R; Schuerman L
    Rev Panam Salud Publica; 2006 Mar; 19(3):179-88. PubMed ID: 16640847
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The immunogenicity and safety of a reduced PRP-content DTPw-HBV/Hib vaccine when administered according to the accelerated EPI schedule.
    Chatterjee S; Rego SJ; D'Souza F; Bhatia BD; Collard A; Datta SK; Jacquet JM
    BMC Infect Dis; 2010 Oct; 10():298. PubMed ID: 20950457
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The immunogenicity and reactogenicity of DTPw-HBV/Hib 2.5 combination vaccine: results from four phase III multicenter trials across three continents.
    Ortega-Barrìa E; Kanra G; Leroux G; Bravo L; Safary A; Lefevre I;
    Vaccine; 2007 Dec; 25(50):8432-40. PubMed ID: 17961876
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The development of a new heptavalent diphtheria-tetanus-whole cell pertussis-hepatitis B-Haemophilus influenzae type b-Neisseria meningitidis serogroups A and C vaccine: a randomized dose-ranging trial of the conjugate vaccine components.
    Gatchalian S; Palestroque E; De Vleeschauwer I; Han HH; Poolman J; Schuerman L; Dobbelaere K; Boutriau D
    Int J Infect Dis; 2008 May; 12(3):278-88. PubMed ID: 17981067
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Primary and booster vaccination with DTPw-HB/Hib pentavalent vaccine in Costa Rican children who had received a birth dose of hepatitis B vaccine.
    Faingezicht I; Avila-Aguerro ML; Cervantes Y; Fourneau M; Clemens SA
    Rev Panam Salud Publica; 2002 Oct; 12(4):247-57. PubMed ID: 12431356
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A fully liquid DTPw-HepB-Hib combination vaccine for booster vaccination of toddlers in El Salvador.
    Suárez E; Asturias EJ; Hilbert AK; Herzog C; Aeberhard U; Spyr C
    Rev Panam Salud Publica; 2010 Feb; 27(2):117-24. PubMed ID: 20339615
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Reactogenicity and immunogenicity profiles of a novel pentavalent diphtheria-tetanus-whole cell pertussis-hepatitis B and Haemophilus influenzae type B vaccine: a randomized dose-ranging trial of the Hib tetanus-conjugate content.
    Hla KH; Thein SA; Aye A; Han HH; Bock HL; David MP; Schuerman L
    Pediatr Infect Dis J; 2006 Aug; 25(8):706-12. PubMed ID: 16874170
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinical experience with DTPw-HBV and DTPw-HBV/Hib combination vaccines.
    Prymula R; Plisek S
    Expert Opin Biol Ther; 2008 Apr; 8(4):503-13. PubMed ID: 18352853
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Safety and immunogenicity of a new fully liquid DTPw-HepB-Hib combination vaccine in infants.
    Kanra G; Kara A; Demiralp O; Contorni M; Hilbert AK; Spyr C; Viviani S
    Hum Vaccin; 2006; 2(4):155-60. PubMed ID: 17012890
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Immunogenicity, safety, and reactogenicity of the 10-valent pneumococcal non-typeable Hemophilus influenzae protein D conjugate vaccine (PHiD-CV) when co-administered with the DTPw-HBV/Hib vaccine in Indian infants: a single-blind, randomized, controlled study.
    Lalwani S; Chatterjee S; Chhatwal J; Verghese VP; Mehta S; Shafi F; Borys D; Moreira M; Schuerman L
    Hum Vaccin Immunother; 2012 May; 8(5):612-22. PubMed ID: 22634448
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Safety and immunogenicity of a primary course and booster dose of a combined diphtheria, tetanus, acellular pertussis, hepatitis B and inactivated poliovirus vaccine.
    Meriste S; Lutsar I; Tamm E; Willems P
    Scand J Infect Dis; 2006; 38(5):350-6. PubMed ID: 16709537
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Immunogenicity and reactogenicity of a combined DTPw-hepatitis B vaccine in Lithuanian infants.
    Usonis V; Bakasenas V; Taylor D; Vandepapeliere P
    Eur J Pediatr; 1996 Mar; 155(3):189-93. PubMed ID: 8929726
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A randomized, controlled trial to assess the immunogenicity and safety of a heptavalent diphtheria, tetanus, pertussis, hepatitis B, poliomyelitis, hib and meningococcal serogroup C combination vaccine administered at 2, 3, 4 and 12-18 months of age.
    Szenborn L; Czajka H; Brzostek J; Konior R; Caubet M; Ulianov L; Leyssen M
    Pediatr Infect Dis J; 2013 Jul; 32(7):777-85. PubMed ID: 23838777
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.